(13) Other operating income
Accounting and measurement policies
Other operating income
Other operating income comprises all income that cannot be allocated to net sales or finance income on account of its character.
Income from upfront payments, milestone payments and royalties
Income from upfront payments, milestone payments and royalties comprises consideration received by the Group from contract partners that are not customers. This relates in particular to collaboration and out-licensing agreements in the Healthcare business sector (see Note (7) “Collaboration and licensing agreements”).
Income from the revaluation of contingent considerations
The accounting treatment of contingent consideration agreed at the sale of a business as defined in IFRS 3 is shown in Note (36) “Other financial assets”.
Other operating income was broken down as follows:
€ million |
|
2024 |
|
2023 |
|---|---|---|---|---|
Income from upfront payments, milestone payments and royalties |
|
56 |
|
53 |
Income from the revaluation of contingent considerations |
|
48 |
|
66 |
Income from the reversal of risk provisions for tax audits |
|
25 |
|
– |
Income from fair value measurement of assets |
|
23 |
|
27 |
Realized gains from currency translation |
|
19 |
|
15 |
Income from miscellaneous services |
|
12 |
|
13 |
Income from the disposal of businesses and assets |
|
11 |
|
137 |
Income from the reversal of provisions for litigation |
|
8 |
|
25 |
Currency effects from operating activities |
|
5 |
|
37 |
Rental income |
|
5 |
|
4 |
Reversal of impairment losses on non-financial asset |
|
– |
|
6 |
Remaining other operating income |
|
57 |
|
62 |
Other operating income |
|
269 |
|
445 |
Income from upfront payments, milestone payments and royalties primarily comprises license income for interferon beta products (Biogen Inc., United States).
As in the previous year, income from the revaluation of contingent considerations mainly relates to a revaluation following the achievement of milestones in connection with the biosimilars business that was sold to a subsidiary of Fresenius SE & Co. KGaA, Bad Homburg vor der Höhe, in 2017.
In the previous year, income from disposals of businesses and assets primarily related to income from the disposal of a non-strategic brand in the Healthcare business sector and a portfolio of licenses and patents in the Electronics business sector.
For information on income from the reversal of provisions for litigation, see Note (27) “Other provisions”.